| Literature DB >> 32532797 |
Cristina Drenkard1, Kirk Easley2, Gaobin Bao3, Charmayne Dunlop-Thomas3, S Sam Lim3, Teresa Brady4.
Abstract
BACKGROUND: African-Americans are historically under-represented in SLE studies and engaging them in behavioural interventions is challenging. The Women Empowered to Live with Lupus (WELL) study is a trial conducted to examine the effectiveness of the Chronic Disease Self-Management Program (CDSMP) among African-American women with SLE. We describe enrolment and retention challenges and successful strategies of the WELL study.Entities:
Keywords: patient perspective; qualitative research; systemic lupus erythematosus
Mesh:
Year: 2020 PMID: 32532797 PMCID: PMC7295441 DOI: 10.1136/lupus-2020-000391
Source DB: PubMed Journal: Lupus Sci Med ISSN: 2053-8790
Figure 1Overview of the study design. AA, African–American; CDSMP, Chronic Disease Self-Management Program; GOAL, Georgians Organized Against Lupus; WELL, Women Empowered to Live with Lupus study.
Summary of self-reported measures
| Category | Construct | Measure |
| Demographics | Age | Ad hoc |
| Disease duration | Ad hoc | |
| Education | Ad hoc | |
| Work status | Ad hoc | |
| Health-related quality of life | PROMIS global health-physical | PROMIS SF10 |
| PROMIS global health-mental | PROMIS SF10 | |
| PROMIS depression | PROMIS SF8a | |
| PROMIS physical function | PROMIS SF10b | |
| PROMIS pain interference | PROMIS SF8a | |
| PROMIS fatigue | PROMIS SF8a | |
| PROMIS sleep disturbance | PROMIS SF8a | |
| PROMIS anxiety | PROMIS SF8a | |
| PROMIS anger | PROMIS SF5a | |
| PROMIS ability to participate in social roles and activities | PROMIS SF8a | |
| Self-management | PROMIS self-efficacy to manage medicines | PROMIS SF8a |
| PROMIS self-efficacy to manage symptoms | PROMIS SF4a | |
| Communication with physicians | 3-item Stanford Scale | |
| Patient Activation Measure | PAM | |
| Psychosocial factors | Perceived stress | Cohen Scale 4 |
| PROMIS emotional support | PROMIS SF4a | |
| PROMIS informational support | PROMIS SF4a | |
| PROMIS instrumental support | PROMIS SF4a | |
| PROMIS social isolation | PROMIS SF6a | |
| Everyday discrimination | Williams Everyday Discrimination Scale | |
| Disease severity | Disease activity | SLAQ |
| Organ damage | SA-BILD |
PAM, Patient Activation Measure, used under Insignia Health licence; PROMIS SF, Patient-Reported Outcome Measurement Information System Short Form; SA-BILD, Self-Administered Brief Index of Lupus Damage; SLAQ, Systemic Lupus Activity Questionnaire.
Figure 2Recruitment of the WELL and Usual Care cohorts. CDSMP, Chronic Disease Self-management Program; GOAL, Georgians Organized Against Lupus; SM, self-management; WELL, Women Empowered to Live with Lupus study; WS, workshop.
Baseline characteristics of WELL and Usual Care participants
| Category | Measure | Usual Care | WELL |
| Demographics | Age (years) | 47.3 (14.0) | 49.8 (12.3) |
| Disease duration (years) | 15.4 (10.5) | 16.4 (9.9) | |
| Education (years) | 14.1 (2.8) | 14.3 (2.9) | |
| Work status, n (%) | |||
| Working full time | 147 (27.9) | 28 (16.8) | |
| Working part-time | 63 (12.0) | 11 (6.6) | |
| Retired | 68 (12.9) | 22 (13.2) | |
| Home maker | 29 (5.5) | 2 (1.2) | |
| Student | 17 (3.2) | 4 (2.4) | |
| Unemployed or disabled | 202 (38.4) | 100 (59.9) | |
| Health-related quality of life | PROMIS global health-physical | 40.6 (8.8) | 38.3 (7.5) |
| PROMIS global health-mental | 43.5 (9.2) | 41.4 (9.0) | |
| PROMIS depression | 51.1 (10.9) | 53.5 (9.2) | |
| PROMIS physical function | 40.6 (10.0) | 38.4 (7.6) | |
| PROMIS pain interference | 57.7 (10.1) | 59.0 (9.2) | |
| PROMIS fatigue | 57.5 (11.2) | 58.6 (10.6) | |
| PROMIS sleep disturbance | 56.7 (10.7) | 57.3 (10.8) | |
| PROMIS anxiety | 51.9 (11.4) | 53.9 (10.5) | |
| PROMIS anger | 51.2 (12.5) | 53.0 (11.4) | |
| PROMIS ability to participate in social roles and activities | 47.5 (10.1) | 45.3 (8.3) | |
| Self-management | PROMIS self-efficacy to manage medicines | 46.2 (9.2) | 46.0 (9.0) |
| PROMIS self-efficacy to manage symptoms | 48.3 (8.7) | 47.1 (7.8) | |
| Communication with physicians* | 2.9 (1.1) | 3.1 (1.1) | |
| Patient Activation Measure (PAM), n (%) | |||
| Level 1 (disengaged and overwhelmed) | 39 (7.5) | 12 (7.3) | |
| Level 2 (becoming aware, still struggling) | 123 (23.5) | 24 (14.5) | |
| Level 3 (taking action) | 264 (50.5) | 90 (54.5) | |
| Level 4 (maintain behaviours/push further) | 97 (18.5) | 39 (23.6) | |
| Psychosocial factors | Perceived stress† | 6.3 (3.2) | 6.2 (3.2) |
| PROMIS emotional support | 51.3 (9.3) | 51.4 (9.2) | |
| PROMIS informational support | 53.6 (10.7) | 52.4 (9.9) | |
| PROMIS instrumental support | 53.1 (9.3) | 51.4 (9.2) | |
| PROMIS social isolation | 47.3 (10.9) | 49.9 (10.9) | |
| Everyday discrimination‡ | 1.6 (0.6) | 1.7 (0.6) | |
| Disease severity | Disease activity (SLAQ score)§ | 14.4 (8.7) | 16.9 (8.6) |
| Organ damage score level¶, n (%) | |||
| No damage (SA-BILD score=0) | 112 (21.3) | 29 (17.3) | |
| Mild damage (SA-BILD score=1–2) | 210 (39.8) | 58 (34.5) | |
| Severe damage (SA-BILD score ≥3) | 205 (38.9) | 81 (48.2) |
Statistic values are displayed as mean (SD) unless otherwise specified.
PROMIS measures are reported using a T-score metric in which 50 is the mean and 10 is the SD of a reference population, with higher scores indicating more of the domain being measured.
*Scores range from 0 to 5, with higher scores indicating better communication.
†Scores range from 0 to 16, with higher scores indicating higher perceived stress.
‡Scores range from 1 to 4, with higher scores indicating higher perceptions of discrimination.
§Scores range from 0 to 47, with higher scores indicating higher disease activity.
¶Scores range from 0 to 30, with higher scores indicating higher lupus damage.
PROMIS, Patient-Reported Outcome Measurement Information System Measure; SA-BILD, Self-Administered Brief Index of Lupus Damage; SLAQ, Systemic Lupus Activity Questionnaire; WELL, Women Empowered to Live with Lupus study.
Figure 3Monthly recruitment, CDSMP registration and CDSMP attendance. CDSMP, Chronic Disease Self-management Program; WELL, Women Empowered to Live with Lupus.
Summary of recruitment and retention of African–American women with SLE into the CDSMP: challenges, barriers, strategies and outcomes
| Challenge | Identified barrier | Implemented strategy | Outcome |
| Low registration into a CDSMP workshop. | CDSMP locations and scheduled not matching participants’ needs. | Collaborative Emory-ARC efforts to coordinate CDSMP workshops that would meet study participants’ needs. Support ARC community recruitment efforts. Increased the number of CDSMP workshops at convenient locations and schedules. CDSMP at libraries, health centres, churches, Grady and Emory facilities. CDSMP delivered on Saturdays. Increased the number of study participants registered per workshop (to prevent need to cancel workshops due to low registration). | 42 CDSMP WS scheduled in 2 years. 28 in community centres. 14 in Grady and Emory facilities. 14 CDSMP scheduled on Saturdays. Of 228 participants consented, 203 (89%) registered into a CDSMP. |
| Participant no-shows or cancellation, after being registered into a CDSMP workshop. | Competing health and life-related demands. Unclear understanding of the CDSMP scope and objectives. | CDSMP demonstration (1-hour ‘Session Zero’). Reinvited to register for a different CDSMP workshop. CDSMP workshops on Saturdays. Provided information about the CDSMP at multiple points of the recruitment process. Culturally relevant recruitment material including a short informative/testimonial video with messages highlighting alignment of lupus patients’ self-management needs with the intervention goals and benefits. | 6 ‘Sessions Zero’; 28 attendees. Of 203 participants registered into a CDSMP, 168 (82.8%) attended ≥1 class. Attendance increased from 45 participants in the first half of the recruitment period to 123 participants in the second half. 64 of 168 (38%) attended a Saturday-delivered CDSMP workshop. |
| Low CDSMP completion rate (less than four classes attendance). | Health and life-related demands. Variable transportation needs. Forgetfulness. | Option to attend future CDSMP workshops. Flexible transportation options across the 6-week CDSMP. Weekly reminder via phone call/text message. Non-monetary incentive at class 3. | The completion rate increased from 64.7% in the first 6 months since the intervention started to 80.0% in the second 6 months. The cumulative completion rate was 75.0% for the 2-year study period. |
| Low rate of 6-month survey response. | Competing demands. Forgetfulness. | Frequent, personalised contact by study staff. Survey reminders. Implemented a ±3-month window to complete the survey. Flexible survey delivery. Monetary and non-monetary incentives. | The 6-month response rate was 80.9% for year 1 CDSMP participants and 98.9% for year 2 CDSMP participants. By 30 September 2019, the overall 6-month response rate was 92.3%. |
ARC, Atlanta Regional Commission, an Atlanta-based organisation that owns the CDSMP licence; CDSMP, Chronic Disease Self-Management Program; WS, workshop.